Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Filings indexed 1,403 across all filing types
Latest filing 2026-05-06 Foreign Filer Report
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
6-K - Innate Pharma SA (0001598599) (Filer)
Foreign Filer Report
2026-05-06 English
Inside Information / Other news releases
Regulatory Filings
2026-05-06 English
Informations privilégiées / Autres communiqués
Regulatory Filings
2026-05-06 French
6-K - Innate Pharma SA (0001598599) (Filer)
Foreign Filer Report
2026-04-23 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release (“COMMUNIQUÉ DE PRESSE”) announcing that Innate Pharma’s management will participate in a third-party investor conference (D. Boral Capital Global Conference). It does not contain financial results, AGM materials, proxy solicitations, share issues, or other specialized filings. It is a routine corporate announcement about upcoming investor outreach, best classified under the general regulatory/press release fallback category.
2026-04-23 French
Inside Information / Other news releases
Regulatory Filings Classification · 0% confidence The document is a press release announcing the company’s participation in an upcoming investor conference. It does not contain financial results (so not ER or IR), no board changes (MANG), no dividend (DIV), no share issuance (SHA), no detailed investor slide deck (IP), and is not a statutory report itself. It is a standalone corporate announcement and thus falls into the general “Regulatory Filings” fallback category (RNS).
2026-04-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.